Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1816 results
May 2016
-
Story From Our Labs
Eye disease tracked to a glitch in starburst cells
A cellular computing error wreaks havoc on vision.
-
In The News
Novartis Access perspectives: Fighting Africa's future epidemics
An editorial for the World Economic Forum by Harald Nusser, Head Novartis Access & Malaria Initiative
April 2016
-
Press release
Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional… -
Story Discovery
Collaborating to unlock secrets of the microbiome
Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.
-
Press release
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential… -
Story Patient Perspectives
Patient advocacy at work: one man’s contributions to the COPD community
Read how one caregiver established an association to provide resources for both COPD patients and caregivers.
-
Story Discovery
Talking to: Bruno Strigini on why we're entering a transformative time in cancer care
Accelerating Research to Get Answers Faster
-
Press release
Novartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen Wachstums
Der Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%… -
Press release
Novartis a enregistré un premier trimestre solide, malgré la perte d'exclusivité de Gleevec, et investi dans de nouveaux lancements pour soutenir la croissance à long terme
Chiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9… -
Press release
Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow… -
Press release
Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most… -
Story Discovery
Factory foreman keeps liver’s line workers on task
A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.